Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic Scope & Assumptions
1.4 Region-wise Market Calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based Segment Share Calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising Demand for Artemisinin Combination Therapy (ACT)
3.2.2 Strong product pipeline
3.2.3 Rising Government Initiatives
3.3 Market restraint analysis
3.3.1 Limited number of global manufacturers
3.4 Penetration & growth prospect mapping
3.5 ACT - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
Chapter 4 Artemisinin Combination Therapy (ACT) Market: Type Outlook
4.1 ACT market by type, movement analysis
4.2蒿甲醚-Lumefantrine
4.2.1 Artemether-Lumefantrine Market estimates and forecast, 2014 - 2025 (USD Million)
4.3 Artesunate-Amodiaquine
4.3.1 Artesunate-Amodiaquine Market estimates and forecast, 2014 - 2025 (USD Million)
4.4 Dihydroartemisinin-Piperaquine
4.4.1 Dihydroartemisinin-Piperaquine Market estimates and forecast, 2014 - 2025 (USD Million)
4.5 Artesunate-Mefloquine
4.5.1 Artesunate-Mefloquine Market estimates and forecast, 2014 - 2025 (USD Million)
4.6 Artesunate-Sulfadoxine-Pyrimethamine
4.6.1 Artesunate-Sulfadoxine-Pyrimethamine Market estimates and forecast, 2014 - 2025 (USD Million)
4.7 Pyronaridine-Artesunate
4.7.1 Pyronaridine-Artesunate Market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 5 Artemisinin Combination Therapy (ACT) Market: Regional Outlook
5.1 ACT market share by region, 2017 & 2025 (USD Million)
5.2.1 Asia Pacific
5.2.2 China
5.2.3 India
5.2.4 Pakistan
5.2.5 Indonesia
5.2.6 Vietnam
5.2 Latin America
5.2.1 Brazil
5.2.2 Colombia
5.3 MEA
5.3.1 Nigeria
5.3.2 Democratic Republic of Congo
5.3.3 Mali
5.3.4 Uganda
5.3.5 Kenya
5.4 RoW
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.2.1 Company Profiles
6.2.2 KPC Pharmaceuticals, Inc
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Guilin Pharmaceutical Co., Ltd
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Product benchmarking
6.2.3.4 Strategic initiatives
6.2.4赛诺菲
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Strategic initiatives
6.2.5 Desano Inc.
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives
6.2.6 Calyx Chemicals & Pharmaceutical Ltd.
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Mylan N.V
6.2.7.1 Company overview
6.2.7.2财务业绩
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 Novartis AG
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.8.4 Strategic initiatives
6.2.9 DENK PHARMA GmbH & Co.KG
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 Hovid-Integrated全球制药部分ner
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.10.4 Strategic initiatives
6.2.11 Ipca Laboratories Ltd.
6.2.11.1 Company overview
6.2.11.2 Financial performance
6.2.11.3 Product benchmarking
6.2.11.4 Strategic initiatives
6.2.12 Shelys Africa Pharmaceuticals Ltd.
6.2.12.1 Company overview
6.2.12.2 Financial performance
6.2.12.3 Product benchmarking
6.2.12.4 Strategic initiatives
6.2.13 Cipla Inc.
6.2.13.1 Company overview
6.2.13.2 Financial performance
6.2.13.3 Product benchmarking
6.2.13.4 Strategic initiatives

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain-based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market summary
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Market restraint relevance analysis (Current & future impact)
FIG. 10 Penetration & growth prospect mapping
FIG. 11 SWOT Analysis, By Factor (political & legal, economic, and technological)
FIG. 12 Porter’s Five Forces Analysis
FIG. 13 ACT market, Type outlook key takeaways
FIG. 14 ACT market: Type movement analysis
FIG. 15 Global Artemether-Lumefantrine market, 2014 - 2025 (USD Million)
FIG. 16 Global Artesunate-Amodiaquine market, 2014 - 2025 (USD Million)
FIG. 17 Global Dihydroartemisinin-Piperaquine market, 2014 - 2025 (USD Million)
FIG. 18 Global Artesunate-Mefloquine market, 2014 - 2025 (USD Million)
FIG. 19 Global Artesunate-Sulfadoxine-Pyrimethamine market, 2014 - 2025 (USD Million)
FIG. 20 Global Pyronaridine-Artesunate market, 2014 - 2025 (USD Million)
FIG. 21 Regional market place: Key takeaways
FIG. 22 Regional outlook, 2015 & 2025
FIG. 23 Asia Pacific ACT market, 2014 - 2025 (USD Million)
FIG. 24 China ACT market, 2014 - 2025 (USD Million)
FIG. 25 India ACT market, 2014 - 2025 (USD Million)
FIG. 26 Pakistan ACT market, 2014 - 2025 (USD Million)
FIG. 27 Indonesia ACT market, 2014 - 2025 (USD Million)
FIG. 28 Vietnam ACT market, 2014 - 2025 (USD Million)
FIG. 29 Latin America ACT market, 2014 - 2025 (USD Million)
FIG. 30 Brazil ACT market, 2014 - 2025 (USD Million)
FIG. 31 Colombia ACT market, 2014 - 2025 (USD Million)
FIG. 32 MEA ACT market, 2014 - 2025 (USD Million)
FIG. 33 Nigeria ACT market, 2014 - 2025 (USD Million)
FIG. 34 Democratic Republic of Congo ACT market, 2014 - 2025 (USD Million)
FIG. 35 Mali ACT market, 2014 - 2025 (USD Million)
FIG. 36 Uganda ACT market, 2014 - 2025 (USD Million)
FIG. 37 Kenya ACT market, 2014 - 2025 (USD Million)
FIG. 38 RoW ACT market, 2014 - 2025 (USD Million)
FIG. 39 Strategy framework
FIG. 40 Participant categorization